Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY
New York, Jan 12, 2026, 20:02 EST — Market closed Alnylam Pharmaceuticals’ shares fell sharply on Monday after the drugmaker’s preliminary fourth-quarter sales for its flagship heart drug Amvuttra came in below Wall Street expectations. The decline hit as investors digested the company’s new five-year strategy and 2026 revenue outlook, rolled out around the J.P. Morgan Healthcare Conference in San Francisco. Why it matters now: early-January “preannouncements” can reset the bar ahead of earnings season, and Amvuttra has become Alnylam’s core growth driver. A small miss on that product can outweigh upbeat long-range targets, at least for a session or